Endo International

Endo International Plc operates as a pharmaceutical company, which engages in the development, manufacture, and distribution of branded and generic pharmaceutical products. It operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. The Branded Pharmaceuticals segment conducts certain operations in the U.S. through leased and owned manufacturing properties in Pennsylvania, New York and New Jersey, as well as certain administrative and R&D functions through leased properties in Pennsylvania. The Sterile Injectables segment includes manufacturing, quality assurance, research and development, and administration functions. The Generic Pharmaceuticals segment is composed of manufacturing, distribution, quality assurance and administration functions, as well as certain research and development functions. The International Pharmaceuticals segment’s operations are currently conducted through Paladin’s leased headquarters in Montreal, Canada. The company was founded in 1997 and is headquartered Dublin, Ireland.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. The company’s Endo Pharmaceuticals segment offers branded prescription products,.

Endo International PLC

Bankrupt drugmaker Endo International said on Tuesday a U.S. Bankruptcy Court has approved its restructuring plan and related opioid settlements to emerge from bankruptcy, which began in 2022.

Drugmaker Endo receives US court approval for bankruptcy restructuring

The U.S. Department of Justice said Thursday that it has reached a $465 million settlement with bankruptcy drugmaker Endo International, resolving the federal government's law enforcement, tax, and health care cost claims.

Drugmaker Endo reaches $465 mln bankruptcy settlement with US government

MONTREAL , June 12, 2023 /PRNewswire/ - C3i Center Inc and Paladin Labs Inc., a subsidiary of Endo International plc (NASDAQ: ENDP), have partnered to launch a complimentary clinical testing program for the diagnosis of the T315I mutation in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) patients in Canada. "We're pleased to be working with Paladin Labs to offer this innovative and important testing program that will provide physicians and patients with additional information to guide treatment decisions," says Dr Lambert Busque, Chief Medical Officer of C3i.

C3i partners with Paladin Labs Inc. to offer Canadian clinicians a complimentary testing service to detect T315I mutation

ADMA Biologics

Volcon

Which meme penny stocks are you buying right now? The post How to Invest in Meme Penny Stocks in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Invest in Meme Penny Stocks in 2022

Endo (ENDP) finally files for bankruptcy after negotiations with its debtholders as litigation claims continue to weigh on the business.

Endo (ENDP) Files for Bankruptcy Amid Litigations, Huge Debt

The generic drugmaker faces thousands of lawsuits related to its alleged role in the opioid crisis.

Weighed Down by Opioid Litigation, Endo International Files for Bankruptcy

Oxycodone maker Endo International files for bankruptcy and will put itself up for sale.

Percocet maker Endo International files for bankruptcy

Sale Transaction Would Result in a Substantial Reduction of Debt and Contemplates Purchaser-Established Voluntary Trusts Funded with $550 Million to Benefit Opioid Claimants Patients and Customers Will Continue to Receive Highest Quality Products and Excellent Service Ample Liquidity to Fund Day-to-Day Operations and Ordinary Course Investments During Court-Supervised Process DUBLIN , Aug. 16, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo" or the "Company") today announced that it has entered into a restructuring support agreement ("RSA") with holders of more than a majority of Endo's first lien debt on a sale transaction that would substantially reduce outstanding indebtedness, address remaining opioid and other litigation-related claims, and best position Endo for the future. This will allow Endo to advance its business transformation with a strengthened balance sheet to create compelling value for its stakeholders over the long term.

Endo Enters Into Restructuring Support Agreement with Senior Secured Debtholders to Strengthen Financial Position and Advance Ongoing Business Transformation

Timber Pharmaceuticals

T2 Biosystems

Here's what you need to know about trading penny stocks on August 10th The post Best Penny Stocks to Buy Now? 3 For Your August List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy Now? 3 For Your August List

Endo International plc (ENDP) has announced its Q2 2022 results, which revealed the company's possiblity of filing Chapter 11. These are the details.

Endo International Discloses Bankruptcy Possibility In Q2 2022 Results

It hasn't been a good run for Endo International (NASDAQ: ENDP ), and Tuesday isn't making it any better. Shares of ENDP stock are down more than 40% today and almost 60% from last week's high.

Endo International (ENDP) Stock Plunges Amid Bankruptcy Warning

Endo (ENDP) delivered earnings and revenue surprises of 118.75% and 9.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Endo International (ENDP) Tops Q2 Earnings and Revenue Estimates

SK Biopharmaceuticals is eligible to receive milestones for future approval and commercialization in Canada and Israel PANGYO, South Korea , Aug. 9, 2022 /PRNewswire/ -- SK Biopharmaceuticals, Co., Ltd. announced that Health Canada has accepted Paladin Labs Inc.'s filing of a New Drug Submission (NDS) for cenobamate as an adjunctive therapy for the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy.

New Drug Filing for Cenobamate Accepted for Review in Canada and Israel

DUBLIN , Aug. 9, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the second-quarter ended June 30, 2022. SECOND-QUARTER FINANCIAL PERFORMANCE (in thousands, except per share amounts) Three Months Ended June 30, Six Months Ended June 30, 2022 2021 Change 2022 2021 Change Total Revenues, Net $         569,114 $         713,830 (20) % $      1,221,373 $      1,431,749 (15) % Reported (Loss) Income from Continuing Operations $     (1,880,883) $          (10,184) NM $     (1,946,183) $           36,875 NM Reported Diluted Weighted Average Shares 235,117 233,331 1 % 234,498 237,043 (1) % Reported Diluted Net (Loss) Income per Share from Continuing Operations $              (8.00) $              (0.04) NM $              (8.30) $                0.16 NM Reported Net (Loss) Income $     (1,885,427) $          (15,500) NM $     (1,957,401) $            26,024 NM Adjusted Income from Continuing Operations (2)(3) $              6,532 $         147,121 (96) % $         162,471 $          322,038 (50) % Adjusted Diluted Weighted Average Shares (1)(2) 236,217 235,416 — % 236,466 237,043 — % Adjusted Diluted Net Income per Share from Continuing Operations (2)(3) $                0.03 $                0.62 (95) % $                0.69 $                1.36 (49) % Adjusted EBITDA (2)(3) $          160,206 $          337,700 (53) % $          471,132 $          702,415 (33) % __________ (1) Reported Diluted Net (Loss) Income per Share from Continuing Operations is computed based on weighted average shares outstanding and, if there is income from continuing operations during the period, the dilutive impact of ordinary share equivalents outstanding during the period.

ENDO REPORTS SECOND-QUARTER 2022 FINANCIAL RESULTS

Lottery.com

Exela Technologies

Here's what you need to know about trading penny stocks on August 4th The post Best Penny Stocks to Buy Premarket on August 4th? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy Premarket on August 4th? 3 to Watch

Amarin Corporation Plc

FuboTV

Canoo

Penny stocks to buy? Here's what options traders think.

4 Best Penny Stocks To Buy On Reddit According To Options Traders

NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates and clients, “BHG” or “we”), the New York City-based investment advisor to clients with financial interests in Endo International Plc. (“Endo” or the “Company”) (NASDAQ: ENDP),today issued an open letter to directors of the Company and its financial auditor, PricewaterhouseCoopers LLP, relating to financial disclosures.. The full open letter to the Company's directors, along with the private lett

Buxton Helmsley Issues Letter to Endo International Plc. Directors, Relating to Financial Disclosures

Endo's (ENDP) subsidiary, Endo Ventures, signs agreement with Quoin Pharmaceuticals for developing/commercializing the latter's pipeline candidate, QRX003, for treating Netherton syndrome in Canada.

Endo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada

Quoin Pharmaceuticals Ltd

The product is under investigation for the treatment of Netherton syndrome, a rare disease DUBLIN , July 15, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into agreements with Quoin Pharmaceuticals Inc. (NASDAQ: QNRX) for the development, registration, supply, commercialization and distribution of QRX003 on an exclusive basis in Canada. If the product is approved, Paladin Labs Inc., an operating company of Endo, will be responsible for all commercial activities in Canada.

Endo Announces Agreement for Paladin Labs to Develop, Commercialize and Supply Quoin Pharmaceuticals' QRX003 in Canada

After a week of roller-coaster price action, ENDP stock is on the upswing even after Endo International posts disappointing clinical results. The post Why Is Endo International (ENDP) Stock Up Today?

Why Is Endo International (ENDP) Stock Up Today?

Tyme Technologies

Ra Medical Systems Inc

Titan Pharma

Penny stocks to watch with news The post Penny Stocks To Watch: Why KRKR, RMED, TYME, TTNP & ENDP Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Watch: Why KRKR, RMED, TYME, TTNP & ENDP Stock Are Moving

Endo (ENDP) mid-stage study of collagenase clostridium histolyticum (or CCH) for treating frozen shoulder disappoints.

Endo (ENDP) Phase II Study for Frozen Shoulder Disappoints

DUBLIN , July 1, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that a federal jury in Chicago, Illinois, has returned a verdict in favor of the Company's subsidiaries Endo Pharmaceuticals Inc. and Endo Health Solutions Inc. (collectively Endo), in an antitrust trial. As Endo previously disclosed, it has been involved since 2014 in various legal proceedings filed by multiple plaintiffs, including classes of direct and indirect purchasers, which have been consolidated in the United States District Court for the Northern District of Illinois under the caption In re Opana® ER Antitrust Litigation.

Opana® ER Antitrust Trial Concludes With Jury Verdict in Endo's Favor

Endo International PLC (NASDAQ: ENDP) shares are trading lower by 16.86% to $0.39 after the company provided top-line results from its Phase 2 study of CCH in patients with adhesive capsulitis of the shoulder, saying "the difference compared to those study participants receiving placebo.

Why Endo International Shares Are Getting Hammered Today

Endo International plc (NASDAQ: ENDP) has announced topline results from its Phase 2 study of collagenase clostridium histolyticum (CCH) in participants with adhesive capsulitis (AC) of the shoulder (frozen shoulder). While participants receiving up to three doses of CCH showed some.

News for Endo International Stock (ENDP)